



Q3 AND YEAR END RESULTS (1 MAY – 31 DEC 2020)

F.R. Martelet, M.D., CEO

19 February 2021

Forward-looking statement

IMPORTANT NOTICE

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

Today's speakers



FRANCOIS MARTELET, M.D.
Chief Executive Officer



ROBERT MAIORANA
*Acting Chief Financial
Officer/Finance Manager*

2020 – a year of delivery and transformation



A clearly defined strategy: key achievements May – December 2020

1

Execute on Apealea® global partnership with Elevar

- US regulatory pathway identified by Elevar
- Commercialization deals signed for Europe, MENA
- Global Named Patient program launched
- Planned commercial partnerships in Asia & LatAm

2

Enhancement & partnering of technology platforms

- Work underway to potentially enhance XR-17™
- Additional platforms in development incl. XR-18 and XR-19 for combination therapy
- Increased focus on partnering to leverage proven R&D and regulatory skills

3

Clinical development of Docetaxel micellar

- Ready to enter Phase 1b
- Development agreement with SAKK
- Large global market opportunity

4

In- & out-licensing, partnering & M&A in oncology


- Extensive discussions ongoing to acquire promising oncology assets
- Boutique investment firms driving process to partner or out-license Animal Health assets and XR-17™ technology platform

Q3 and Year end Financial Highlights^{1,2}

- Cash and cash equivalents & short-term investments TSEK 287,405 (325,658)
- Consolidated net sales TSEK 482 (565)
- Operating profit/loss TSEK -131,493 (-117,256)
 - Cash burn to reduce over the next two years to 10-12 MSEK per month
- Net profit/loss after tax TSEK -140,270 (-93,263)
- Earnings per share SEK -0.31 (-0.36)

1. Figures in brackets show outcomes for the corresponding period of the previous financial year.
2. From January 1, 2021, Oasmia will switch to calendar-year financial reporting. This year-end report therefore covers an abbreviated financial year for the period May 1 – December 31, 2020. The third quarter is abbreviated to cover the period November 1 - December 31, 2020. The comparative figures for the previous year report the same periods in 2019.

Maximizing Apealea® - global commercialization progressing well



Expanding the portfolio and pipeline with a focus on oncology

Product	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration / approval	Commercial Launch	Geography
---------	------------	--------------	---------	---------	---------	-------------------------	-------------------	-----------

Human Health Portfolio

Apealea® / Paclical® (paclitaxel) ¹	Ovarian cancer								USA
	Ovarian cancer								EU / EEA
Docetaxel micellar	Prostate cancer								Global



Animal Health Portfolio (Canines)


Paccal vet (paclitaxel)	Mammary Carcinoma								USA
Doxophos vet (doxorubicin)	Lymphoma								USA

Improving and expanding the use of our technologies




Docetaxel micellar – initiating phase 1b to target prostate cancer

- Docetaxel approved for wide range of solid malignancies
- Standard of care for advanced prostate cancer
- Docetaxel micellar uses XR-17™ to enable IV administration of docetaxel without solubility enhancers
- SAKK (Swiss Group for Clinical Cancer Research) to initiate Phase 1b trial early 2021



In-licensing opportunities mainly in oncology

- We're looking to in-license oncology products from pre-clinical up to late Phase 3 development



- We're also pursuing collaborations to support partners' R&D and overcome solubility challenges

Focusing resources to invest in high growth opportunities

Ongoing process to partner Animal Health assets

Paccal Vet

- XR-17™-based formulation of paclitaxel for mastocytoma in dogs

Doxophos Vet

- XR-17-based formulation of doxorubicin for lymphoma, common cancer in dogs
- Phase 1 & 2 results to form part of FDA conditional approval application; Phase 3 required for registration

Strategic review to identify cost savings and synergies

- Annualized cost savings of more than SEK 100m delivered
- Reduced cash burn below SEK 10 - 12 million / month
- Lean, focused and agile structure
- 29 employees down from 61 last year
- Moving HQ to Stockholm while Uppsala R&D laboratories remain

Building a new leadership team for success



FRANCOIS MARTELET,
M.D., Master's Degree Business
Chief Executive Officer



FREDRIK JÄRRSTEN*
Chief Finance Officer



DR HEIDI B. RAMSTAD
M.D.
Chief Medical Officer



REINHARD KOENIG, M.D.
*Acting Chief Scientific
Officer*



ELIN TRAMPE, M.A.
Chief Technical Officer



PETER SELIN, B.Sc.
Chief Business Officer



ANDERS HÄRFSTRAND,
M.D., Ph.D.
Non-executive Chairman



HEGE HELLSTRÖM, B.A.
Board Member



PETER ZONABEND,
LL.M, EMLE
Board Member



**BIRGIT STATTIN
NORINDER, M.Sc.**
Board Member

Looking ahead – multiple catalysts to drive value in 2021

Potential near- and mid-term value drivers

- Elevar partnering for Apealea® in key territories, milestone payments and royalties
- XR-18 platform development and XR-19 lab proof of concept
- SAKK docetaxel micellar Phase 1b preparations well underway
- Partnering of XR-17™ and Animal Health assets
- Progress on M&A and in-licensing to build critical mass in oncology



Thank you!

Oasmia Pharmaceutical AB (STO: OASM)
Vallongatan 1
752 28 Uppsala
Sweden



+46 018-50 54 40



IR@oasmia.com



www.oasmia.com



www.linkedin.com/company/oasmia-pharmaceutical-ab



www.twitter.com/Oasmia